Clinical significance and different levels of urinary monocyte chemoattractant protein-1 in Type 2 diabetes mellitus

Diabetes Research and Clinical Practice

Volumn 83, Issue 2, 2009, Pages 215-219

  Qiu yue, Wang ^a   Fen qin, Chen ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Diabetes mellitus; Diabetic nephropathy; Monocyte chemoattractant protein 1

Indexed keywords

CREATININE; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCYTE CHEMOTACTIC PROTEIN 1; TRIACYLGLYCEROL;

ADULT; AGED; ALBUMINURIA; ARTICLE; BLOOD PRESSURE MEASUREMENT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DISEASE SEVERITY; FEMALE; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PROTEIN SECRETION; PROTEIN URINE LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL;

ADULT; AGED; ALBUMINURIA; CASE-CONTROL STUDIES; CHEMOKINE CCL2; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS;

EID: 58249108699     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2008.09.048     Document Type: Article

References (21)

1. Banba N., Nakamura T., Matsumura M., Kuroda H., Hattori Y., and Kasai K. Possible relationship of monocyte chemoattractant protein-1 with diabetic nephropathy. Kidney Int. 58 2 (2000) 684-690
2. Piemonti L., Leone B.E., Nano R., Saccani A., Monti P., Maffi P., et al. Human pancreatic islets produce and secrete mcp-1/ccl2: relevance in human islet transplantation. Diabetes 51 1 (2002) 55-65
3. Kiyici S., Erturk E., Budak F., Ersoy C., Tuncel E., Duran C., et al. Serum monocyte chemoattractant protein-1 and monocyte adhesion molecules in type 1 diabetic patients with nephropathy. Arch. Med. Res. 37 8 (2006) 998-1003
4. Takebayashi K., Matsumoto S., Aso Y., and Inukai T. Association between circulating monocyte chemoattractant protein-1 and urinary albumin excretion in nonobese Type 2 diabetic patients. J. Diab. Comp. 20 2 (2006) 98-104
5. Morii T., Fujita H., Narita T., Shimotomai T., Fujishima H., Yoshioka N., et al. Association of monocyte chemoattractant protein-1 with renal tubular damage in diabetic nephropathy. J. Diab. Comp 17 1 (2003) 11-15
6. Rovin B.H., Doe N., and Tan L.C. Monocyte chemoattractant protein-1 levels in patients with glomerular disease. Am. J. Kidney Dis. 27 (1996) 640-646
7. Tashiro K., Koyanagi I., Saitoh A., Shimizu A., Shike T., Ishiguro C., et al. Urinary levels of monocyte chemoattractant protein-1 (MCP-1) and interleukin-8 (IL-8), and renal injuries in patients with type 2 diabetic nephropathy. J. Clin. Lab. Anal. 16 1 (2002) 1-4
8. Galkina E., and Ley K. Leukocyte recruitment and vascular injury in diabetic nephropathy. J. Am. Soc. Nephrol. 17 2 (2006) 368-377
9. Amann B., Tinzmann R., and Angelkort B. ACE inhibitors improve diabetic nephropathy through suppression of renal MCP-1. Diab. Care 26 8 (2003) 2421-2425
10. Chiarelli F., Cipollone F., Mohn A., Marini M., Iezzi A., Fazia M., et al. Circulating monocyte chemoattractant protein-1 and early development of nephropathy in type 1 diabetes. Diab. Care 25 10 (2002) 1829-1834
11. Chow F.Y., Nikolic-Paterson D.J., Ozols E., Atkins R.C., Rollin B.J., and Tesch G.H. Monocyte chemoattractant protein-1 promotes the development of diatetic renal injury in streptozotocin-treated mice. Kidney Int. 69 1 (2006) 73-80
12. Kumar S.N., and Boss J.M. Site A of the mcp-1 distal regulatory region functions as a transcriptional modulator through the transcription factor NF1. Mol. Immunol. 37 11 (2000) 623-632
13. Lee F.T., Cao Z., Long D.M., Panagiotopoulos S., Jerums G., Cooper M.E., et al. Interactions between angiotensin II and NF-κBdependent path ways in modulating macrophage infiltration in experimental diabetic nephropathy. J. Am. Soc. Nephrol. 15 8 (2004) 2139-2151
14. Mezzano S., Aros C., Droguett A., Burgos M.E., Ardiles L., Flores C., et al. NF-κB activation and overexpression of regulated genes in human diabetic nephropathy. Nephrol. Dial. Transplant. 19 10 (2004) 2505-2512
15. Ha H., Yu M.R., Choi Y.J., Kitamura M., and Lee H.B. Role of high glucose-induced nuclear factor-κB activation in monocyte chemoattractant protein-1 expression by mesangial cells. J. Am. Soc. Nephrol. 13 4 (2002) 894-902
16. Han S.Y., Kim C.H., Kim H.S., Jee Y.H., Song H.K., Lee M.H., et al. Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechamism in type 2 diabetic rats. J. Am. Soc. Nephrol. 17 5 (2006) 1362-1372
17. Trachtman H., Weiser A.C., Valderrama E., Morgado M., and Palmer L.S. Prevention of renal fibrosis by spironolactone in mice with complete unilateral vreteral obstruction. J. Urol. 172 suppl 4 (2004) S1590-S1594
18. Takebayashi K., Matsumoto S., Aso Y., and Inukai T. Aldosterone blockade attenuates urinay monocyte chemoattractant protein-1 and oxidative stress in patients with type 2 diabetes complicated by diabetic nephropathy. J. Clin. Endocrinol. Metab. 9 16 (2006) 2214-2217
19. Zhang Y., Chen B., Hou X.H., Guan G.J., Liu G., Liu H.Y., et al. Effects of mycophenolate mofetil, valsartan and their combined therapy on preventing podocyte loss in early stage of diabetic nephropathy in rats. Chin. Med. J. (Engl.) 120 11 (2007) 988-995
20. Wu Y.G., Lin H., Qian H., Zhao M., Qi X.M., Wu G.Z., et al. Renoprotective effects of combination of angiotensin converting enzyme inhibitor with mycophenolate mofetil in diabetic rats. Inflamm. Res. 55 5 (2006) 192-199
21. Wu Y.G., Lin H., Qi X.M., Wu G.Z., Qian H., Zhao M., et al. Prevention of early renal injury by mycophenolate mofetil and its mechanism in experimental diabetes. Int. Imun. 6 (2006) 3445-3453